Abstract

Due to the limitations of available in vitro systems and animal models, we lack a detailed understanding of the pathogenetic mechanisms and have minimal treatment options for liver fibrosis. To overcome this barrier, we engineered a live cell imaging system that identifies collagen producing cells in a human multi-lineage hepatic organoid. This system was adapted for use as a microwell-based platform (i.e., microHOs) where exposure to PDGF or TGF{beta}1 induced the formation of thick collagen fibers. Transcriptomic analysis revealed that TGF{beta}1 exposure converted mesenchymal cells into myofibroblast-like cells that contribute to the development of liver fibrosis. When pro-fibrotic intracellular signaling pathways were examined using pharmacological probes, the anti-fibrotic effect of receptor-specific tyrosine kinase inhibitors was limited to the fibrosis induced by the corresponding growth factor, which indicates that their anti-fibrotic efficacy would be limited to fibrotic diseases that were solely mediated by that growth factor. Transcriptomic and transcription factor activation analyses were used to identify pathways that were jointly activated by PDGF and TGF{beta}1. GSK3{beta} or p38 MAPK inhibitors could prevent TGF{beta}1- or PDGF-induced fibrosis in microHOs because they block intracellular signaling pathways that are commonly utilized by the TGF{beta}1 and PDGF receptors. Hence, these studies identified GSK3{beta} and p38 MAPK inhibitors as potential new broad-spectrum therapies for liver fibrosis, and it is likely that other new therapies could subsequently be identified using this microHO system.